BioMarin Pharmaceutical Inc.
BMRN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $776,133 | $825,410 | $745,145 | $747,313 |
| % Growth | -6% | 10.8% | -0.3% | – |
| Cost of Goods Sold | $140,085 | $150,090 | $151,558 | $136,139 |
| Gross Profit | $636,048 | $675,320 | $593,587 | $611,174 |
| % Margin | 82% | 81.8% | 79.7% | 81.8% |
| R&D Expenses | $409,478 | $161,308 | $158,731 | $173,509 |
| G&A Expenses | $0 | $110,200 | $103,600 | $141,000 |
| SG&A Expenses | $268,415 | $232,300 | $206,100 | $266,600 |
| Sales & Mktg Exp. | $0 | $122,100 | $102,500 | $125,600 |
| Other Operating Expenses | $4,847 | $4,825 | $4,863 | $9,658 |
| Operating Expenses | $682,740 | $398,433 | $369,694 | $449,767 |
| Operating Income | -$46,692 | $276,887 | $223,893 | $161,407 |
| % Margin | -6% | 33.5% | 30% | 21.6% |
| Other Income/Exp. Net | $20,368 | $20,981 | $14,196 | $8,232 |
| Pre-Tax Income | -$26,324 | $297,868 | $238,089 | $169,639 |
| Tax Expense | $4,420 | $57,336 | $52,403 | $44,696 |
| Net Income | -$30,744 | $240,532 | $185,686 | $124,943 |
| % Margin | -4% | 29.1% | 24.9% | 16.7% |
| EPS | -0.16 | 1.25 | 0.97 | 0.66 |
| % Growth | -112.8% | 28.9% | 47% | – |
| EPS Diluted | -0.16 | 1.23 | 0.95 | 0.64 |
| Weighted Avg Shares Out | 192,032 | 191,440 | 190,967 | 190,688 |
| Weighted Avg Shares Out Dil | 192,032 | 196,643 | 196,474 | 196,581 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17,854 | $18,827 | $19,013 | $17,680 |
| Interest Expense | $2,579 | $2,679 | $2,863 | $2,577 |
| Depreciation & Amortization | $18,487 | $18,563 | $22,069 | $23,607 |
| EBITDA | -$5,258 | $319,110 | $263,021 | $195,496 |
| % Margin | -0.7% | 38.7% | 35.3% | 26.2% |